Spinout News
EnAcuity raises £1.28m to target safer surgery
20 December 2024
UCLB and Imperial College London spinout EnAcuity has raised a £1.28m in a pre-seed round led by Twin Path Ventures, joined by the London Co-Investment Fund and Crista Galli Ventures.
Dr Maria Leiloglou, EnAcuity’s CEO, commented: “We’re thrilled to begin this journey with such a dedicated investor team. Their shared commitment to our vision of safer surgeries through advanced imaging has been truly invaluable.”
In a statement, EnAcuity said it was grateful to Imperial Enterprise and the Enterprise Lab’s Ben Mumby-Croft, Hiten Thakrar and Dr James Groves, UCL Business and UCLB Business Manager, Dr Weng Wong, the RAEng management team, Urszula Stawik and Angus Baker, and lead investors Twin Path Venture’s Katie Lockwood, John Spindler and Nick Slater for their on-going support.
The EnAcuity team said they were ‘excited to use this momentum to further build and apply EnAcuity’s product: the first-ever software-only clinical solution for hyperspectral imaging.’
Dr Weng Wong said: “It’s great to see how rapidly EnAcuity has developed over the past year. I’m very much looking forward to seeing the next stages of the company’s development.”
Katie Lockwood, Twin Path Venture’s Co-Founding Partner, added: “EnAcuity is an absolutely exceptional team, led by the force of nature that is Dr Maria Leiloglou, developing real-time AI -powered hyperspectral imaging for surgical vision. We believe this will solve major surgical challenges such as the recognition of the functional status of tissue in laparoscopic surgeries. The team is laser-focused on adoption, using a software-only approach —no hardware adaptations or specialist tech needed. We can’t wait to see this tool in the hands of surgeons helping solve seriously unmet needs within the surgical space.”
EnAcuity’s solution is set to transform laparoscopic surgeries by enhancing real-time imaging, helping surgeons more accurately identify functional details in the body that are typically invisible to the human eye.
The pre-seed funding will support clinical validation of the technology in colorectal and gallbladder surgeries at Imperial College Healthcare NHS Trust.
Further Information: